Tag: Cas12a

A one-pot CRISPR/Cas13a-based contamination-free biosensor for low-cost and rapid nucleic acid diagnostics

Available online 13 January 2022, 113994 doi.org/10.1016/j.bios.2022.113994Get rights and content Highlights • A one-pot CRISPR/Cas13a-based visual biosensor for the rapid and low-cost nucleic acid detection is proposed. • With a newly developed tube-in-tube vessel used in the biosensor, aerosol cross contamination could be completely avoided. • The sensor can not…

Continue Reading A one-pot CRISPR/Cas13a-based contamination-free biosensor for low-cost and rapid nucleic acid diagnostics

CRISPR-Cas12a ribonucleoprotein-mediated gene editing in the plant pathogenic fungus Magnaporthe oryzae

. 2021 Dec 24;3(1):101072. doi: 10.1016/j.xpro.2021.101072. eCollection 2022 Mar 18. Affiliations Expand Affiliation 1 Department of Plant Pathology, Kansas State University, Manhattan, KS, USA. Free PMC article Item in Clipboard Jun Huang et al. STAR Protoc. 2021. Free PMC article Show details Display options Display options Format AbstractPubMedPMID . 2021 Dec…

Continue Reading CRISPR-Cas12a ribonucleoprotein-mediated gene editing in the plant pathogenic fungus Magnaporthe oryzae

Rapid and sensitive point-of-care detection of Leptospira by RPA-CRISPR/Cas12a targeting lipL32.,PLOS Neglected Tropical Diseases

Rapid and sensitive point-of-care detection of Leptospira by RPA-CRISPR/Cas12a targeting lipL32. PLOS Neglected Tropical Diseases ( IF 4.411 ) Pub Date : 2022-01-06 , DOI: 10.1371/journal.pntd.0010112 Sirawit Jirawannaporn,Umaporn…

Continue Reading Rapid and sensitive point-of-care detection of Leptospira by RPA-CRISPR/Cas12a targeting lipL32.,PLOS Neglected Tropical Diseases

Immuno-CRISPR assay could help diagnose kidney transplant rejection early on — ScienceDaily

When a patient receives a kidney transplant, doctors carefully monitor them for signs of rejection in several ways, including biopsy. However, this procedure is invasive and can only detect issues at a late stage. Now, researchers reporting in ACS’ Analytical Chemistry have developed a CRISPR-based assay that can sensitively and…

Continue Reading Immuno-CRISPR assay could help diagnose kidney transplant rejection early on — ScienceDaily

Caribou Biosciences to Present at 40th Annual J.P. Morgan Healthcare Conference

BERKELEY, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) — Caribou Biosciences, Inc. (Nasdaq:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that Rachel Haurwitz, Ph.D., Caribou’s president and chief executive officer, will present a corporate update at the 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022 at…

Continue Reading Caribou Biosciences to Present at 40th Annual J.P. Morgan Healthcare Conference

Combining functional hairpin probes with disordered cleavage of CRISPR/Cas12a protease to screen for B lymphocytic leukemia

Available online 4 January 2022, 113941 doi.org/10.1016/j.bios.2021.113941Get rights and content Highlights • The sensor based on the label-free functional hairpin probe and the disordered cleavage of CRISPR/Cas12a was successfully constructed, and it can also accurately distinguish target and non-target genes successfully used for the detection of the Pax-5a gene. •…

Continue Reading Combining functional hairpin probes with disordered cleavage of CRISPR/Cas12a protease to screen for B lymphocytic leukemia

CRISPR/Cas12a-based biosensors for ultrasensitive tobramycin detection with single- and double-stranded DNA activators

Dawei Li received his Bachelor’s degree (2003) and Master’s degree (2006) from Lanzhou University and PhD (2013) from Nanyang Technological University. At present he is an associate professor in college of biology and the environment at Nanjing Forestry University. His current research interests mainly focus on the design and synthesis…

Continue Reading CRISPR/Cas12a-based biosensors for ultrasensitive tobramycin detection with single- and double-stranded DNA activators

Efficient CRISPR/Cas12a-based genome editing toolbox for metabolic engineering in Methanococcus maripaludis

Abstract Methanococcus maripaludis is a fast-growing and genetically tractable methanogen. To become a useful host organism for the biotechnological conversion of CO2 and renewable hydrogen to fuels and value-added products, its product scope needs to be extended. Metabolic engineering requires reliable and efficient genetic tools, in particular for genome editing…

Continue Reading Efficient CRISPR/Cas12a-based genome editing toolbox for metabolic engineering in Methanococcus maripaludis

Clinical Catch-Up: December 20-24 | BioSpace

It was a relatively quiet week in clinical trial news heading into the holidays. Here’s a look. COVID-19-Related Statera Biopharma dosed the first patient in its study of STAT-205 to mitigate COVID-19 progression. The drug is an immune modulator designed to decrease elevated inflammatory responses associated with cytokine production and modulate the…

Continue Reading Clinical Catch-Up: December 20-24 | BioSpace

Researchers Develop Specific and Sensitive Cas12c-based Nucleic Acid Detection Platform

The prokaryotic clustered regularly interspaced short palindromic repeat (CRISPR) and CRISPR-associated (CRISPR/Cas) protein system has been reconstructed for a revolutionary targeted genome modification platform and nucleic acid detection tool. Restricted by the protospacer adjacent motif (PAM) requirement, specificity, and efficiency, more Cas proteins need to be characterized and adapted for…

Continue Reading Researchers Develop Specific and Sensitive Cas12c-based Nucleic Acid Detection Platform

Efficient target cleavage by Type V Cas12a effectors programmed with split CRISPR RNA

doi: 10.1093/nar/gkab1227. Online ahead of print. Regina Shebanova  1 , Natalia Nikitchina  1   2 , Nikita Shebanov  1 , Vladimir Mekler  3 , Konstantin Kuznedelov  3 , Egor Ulashchik  4 , Ruslan Vasilev  5   6 , Olga Sharko  4 , Vadim Shmanai  4 , Ivan Tarassov  2 , Konstantin Severinov  1   3   7 , Nina Entelis  2…

Continue Reading Efficient target cleavage by Type V Cas12a effectors programmed with split CRISPR RNA

A year of ToBRFV

Although 2021 was the year of viruses for the entire world population, it was even more so for growers, who were confronted with the infamous Tomato Brown Rugose Fruit Virus (ToBRFV). It has been quite a ride – which is, unfortunately, not over just yet. In order to give you…

Continue Reading A year of ToBRFV

CRISPR/Cas12a Powered DNA Framework-Supported Electrochemical Biosensing Platform for Ultrasensitive Nucleic Acid Analysis

Nucleic acid analysis using ultrasensitive and simple methods is critically important for the early-stage diagnosis and treatment of diseases. The CRISPR/Cas proteins, guided by a single-stranded RNA have shown incredible capability for sequence-specific targeting and detection. Herein, in order to improve and expand the application of CRISPR/Cas technology to the…

Continue Reading CRISPR/Cas12a Powered DNA Framework-Supported Electrochemical Biosensing Platform for Ultrasensitive Nucleic Acid Analysis

Editas Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for EDIT-301 for the Treatment of Transfusion-Dependent Beta Thalassemia

EDIT-301 is in development as a transformative, one-time treatment for people living with transfusion-dependent beta thalassemia Editas Medicine will initiate a Phase 1/2 clinical trial in 2022 CAMBRIDGE, Mass., Dec. 20, 2021 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that the U.S….

Continue Reading Editas Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for EDIT-301 for the Treatment of Transfusion-Dependent Beta Thalassemia

Analysis of a Cas12a-based gene-drive system in budding yeast

Analysis of a Cas12a-based gene-drive system in budding yeast | Microbiology Society 1887 This is a required field Please enter a valid email address Approval was a Success Invalid data An Error Occurred Approval was partially successful, following selected items could not be processed due to error…

Continue Reading Analysis of a Cas12a-based gene-drive system in budding yeast

Recombinase Polymerase Amplification/Cas12a-Based Identification of Xanthomonas arboricola pv. pruni on Peach

doi: 10.3389/fpls.2021.740177. eCollection 2021. Affiliations Expand Affiliations 1 Key Laboratory of Horticultural Plant Biology, Ministry of Education, Huazhong Agricultural University, Wuhan, China. 2 Hubei Key Laboratory of Plant Pathology, Huazhong Agricultural University, Wuhan, China. Free PMC article Item in Clipboard Mei Luo et al. Front Plant Sci. 2021. Free PMC article…

Continue Reading Recombinase Polymerase Amplification/Cas12a-Based Identification of Xanthomonas arboricola pv. pruni on Peach

Targeted mutagenesis in plants using Beet curly top virus for efficient delivery of CRISPR/Cas12a components

Available online 8 December 2021 doi.org/10.1016/j.nbt.2021.12.002Get rights and content Highlights • An efficient geminiviral vector was developed from Beet curly top virus with a wide host range. • The geminiviral vector delivered CRISPR/Cas components efficiently into plant cells. • A high frequency of both mutagenesis and complete HDR in plant…

Continue Reading Targeted mutagenesis in plants using Beet curly top virus for efficient delivery of CRISPR/Cas12a components

Researchers Engineer a Mini CRISPR Genetic Editing System That Could Be Easier To Deliver Into Cells

CRISPR illustration. Credit: National Institutes of Health A compact and efficient CRISPR-Cas system, named CasMINI, could be broadly useful for cell-engineering and gene-therapy applications because it is easier to deliver into cells. The findings appear in a study that was published on September 3, 2021, in the journal Molecular Cell….

Continue Reading Researchers Engineer a Mini CRISPR Genetic Editing System That Could Be Easier To Deliver Into Cells

Initial Clinical Data from Editas Medicine’s BRILLIANCE

Data to include patient safety assessments and a preliminary analysis of secondary endpoints to evaluate biological activity Abstract selected for oral presentation on September 29 Company to host webcast investor event following the presentation on September 29 at 11:00 a.m. ET CAMBRIDGE, Mass., Sept. 07, 2021 (News) — Editas Medicine, Inc. (Nasdaq:…

Continue Reading Initial Clinical Data from Editas Medicine’s BRILLIANCE

Mini CRISPR Genome Editing System Created

The common analogy for CRISPR gene editing is that it works like molecular scissors, cutting out select sections of DNA. Stanley Qi, assistant professor of bioengineering at Stanford University, likes that analogy, but he thinks it’s time to reimagine CRISPR as a Swiss Army knife. “CRISPR can be as simple as…

Continue Reading Mini CRISPR Genome Editing System Created

Initial Clinical Data from Editas Medicine’s BRILLIANCE Clinical Trial of EDIT-101 for LCA10 to … | News

Data to include patient safety assessments and a preliminary analysis of secondary endpoints to evaluate biological activity Abstract selected for oral presentation on September 29 Company to host webcast investor event following the presentation on September 29 at 11:00 a.m. ET CAMBRIDGE, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) — Editas Medicine, Inc….

Continue Reading Initial Clinical Data from Editas Medicine’s BRILLIANCE Clinical Trial of EDIT-101 for LCA10 to … | News

Compact CasMINI CRISPR Tech Is Easier to Deliver to Cells, Could Have Broad Gene Therapy Potential

Scientists led by a team at Stanford University have developed a compact, efficient CRISPR-Cas system, called CasMINI, which is about half the size of existing CRISPR-Cas systems, and which could have broad utility for gene therapy applications as well as cell engineering. The researchers confirmed in experiments that CasMINI could,…

Continue Reading Compact CasMINI CRISPR Tech Is Easier to Deliver to Cells, Could Have Broad Gene Therapy Potential

Stanford researchers engineer an efficient, multi-purpose, mini CRISPR system

The common analogy for CRISPR gene editing is that it works like molecular scissors, cutting out select sections of DNA. Stanley Qi, assistant professor of bioengineering at Stanford University, likes that analogy, but he thinks it’s time to reimagine CRISPR as a Swiss Army knife. “CRISPR can be as simple…

Continue Reading Stanford researchers engineer an efficient, multi-purpose, mini CRISPR system

Researchers develop the smallest CRISPR to date for genome editing

A compact and efficient CRISPR-Cas system, named CasMINI, could be broadly useful for cell-engineering and gene-therapy applications because it is easier to deliver into cells. The findings appear in a study publishing September 3 in the journal Molecular Cell. This is a critical step forward for CRISPR genome-engineering applications….

Continue Reading Researchers develop the smallest CRISPR to date for genome editing

A mini-CRISPR system could be ‘Swiss knife’ in gene editing

Why grab just a pair of scissors when you could get more functionality with a Swiss knife? A team of researchers at Stanford University think they’ve built such a tool to apply to CRISPR gene editing, which could help advance the platform and make it easier to deliver into cells. the…

Continue Reading A mini-CRISPR system could be ‘Swiss knife’ in gene editing

Industry Trends and Global Forecasts, 2021-2030

INTRODUCTION Clustered regularly interspaced short palindromic repeats (CRISPR) are a family of DNA sequences, which constitute a primitive immune system that is responsible for protecting prokaryotic cells from phage infections. New York, Aug. 24, 2021 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “CRISPR Based Therapeutics Market by…

Continue Reading Industry Trends and Global Forecasts, 2021-2030

Editas Medicine Presents Data on New SLEEK Gene Editing

SLEEK enables high efficiency, multi-transgene knock-in of induced Pluripotent Stem Cells (iPSCs), T cells, and Natural Killer (NK) cells Data support SLEEK as an optimized approach to develop next generation cell therapy medicines CAMBRIDGE, Mass., Aug. 20, 2021 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today…

Continue Reading Editas Medicine Presents Data on New SLEEK Gene Editing